Simon Krauß

[Klaus Metzeler has left Twiitter 🇺🇦 @KlausMetzelerMD]

Clonal hematopoiesis (CH) is common in older persons without hematologic disease - but what about those who previously had acute myeloid leukemia, and survived the disease? @ScimonkM looked at CH in 373 AML long-term survivors: https://t.co/K0dH8mNs2z (1/10)

[Enard/Hellmann Lab @EnardHellmannWG]

We are excited to share our latest manuscript on cis-regulatory evolution in primates:
https://t.co/xnxuJuzNM2
Congrats to @zkliesmete, @IHellmann and all co-authors!

Short summary in a thread below ⬇️

[Simon Krauß @ScimonkM]

@KlausMetzelerMD 😂

[Klaus Metzeler has left Twiitter 🇺🇦 @KlausMetzelerMD]

#proudsupervisor #ASH23

[Klaus Metzeler has left Twiitter 🇺🇦 @KlausMetzelerMD]

Interested in MRD in AML? Stop by at poster #3616 #ASH23 presented by my students Simon Krauß (@ScimonkM) & Tara Holloway.
They established a novel NGS MRD assay based on molecular inversion probes & applied it to measure MRD before alloSCT.

Postercast: https://t.co/hgDWBWFFcF

[Klaus Metzeler has left Twiitter 🇺🇦 @KlausMetzelerMD]

My first in-person ASH after a 3-year hiatus.
Great to be inspired by the atmosphere of innovation, and to connect with colleagues & friends! @tobias_herold @ChrisRauschMUC @ScimonkM #ASH23

[David Steensma, MD @DavidSteensma]

This study by @KlausMetzelerMD #MDS23 on ASXL1 mutation VAF in different marrow anatomical sites underscores potential for spatial variation in clonal patterns - echoed in extreme “focal AML” case by @CKBrierley et al @AjHematology 2012 we diagnosed only by sternal aspiration

[Amanpreet Kaur Bains @BainsAK]

Happy to share my first paper from my doctoral work, a shared effort of Leipzig and Dresden on altered mesenchymal extracellular matrix in MDS.
@UwePlatzbecker #Leipzig #Dresden #ECM #MDS
https://t.co/MhmP9NtYcM

#phd #work #share #ECM

[Marcus Buschbeck and Lab @MarcusBuschbeck]

#Spetses2022

[Klaus Metzeler has left Twiitter 🇺🇦 @KlausMetzelerMD]

@ScimonkM is again looking at AML long-term survivors but from the genetic side. Clonal hematopoiesis is very common in this cohort, but the details matter- e.g. if patients received an allo or chemo only. Have a look at his poster 416!